Gene · 104
Papers2,137
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
481 to 500 of 2,137
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The Emerging Role of RNA Modifications in the Regulation of Antiviral Innate Immunity. | Front Microbiol | 2022 | 35185855 | PubTator, text mining | PubMed |
| Poor evidence for host-dependent regular RNA editing in the transcriptome of SARS-CoV-2. | J Appl Genet | 2022 | 35179717 | PubTator, text mining | PubMed |
| Aberrant Expression of ADARB1 Facilitates Temozolomide Chemoresistance and Immune Infiltration in Glioblastoma. | Front Pharmacol | 2022 | 35177985 | PubTator, text mining | PubMed |
| Using publicly available transcriptomic data to identify mechanistic and diagnostic biomarkers in azoospermia and overall male infertility. | Sci Rep | 2022 | 35173218 | PubTator, text mining | PubMed |
| N-6-Methyladenosine in Vasoactive microRNAs during Hypoxia; A Novel Role for METTL4. | Int J Mol Sci | 2022 | 35162982 | PubTator, text mining | PubMed |
| Disparities in Lung Cancer: miRNA Isoform Characterization in Lung Adenocarcinoma. | Cancers (Basel) | 2022 | 35159038 | PubTator, text mining | PubMed |
| Crosstalk Between Four Types of RNA Modification Writers Characterizes the Tumor Immune Microenvironment Infiltration Patterns in Skin Cutaneous Melanoma. | Front Cell Dev Biol | 2022 | 35155433 | PubTator, text mining | PubMed |
| The Basis and Promise of Programmable RNA Editing and Modification. | Front Genet | 2022 | 35154288 | PubTator, text mining | PubMed |
| The Identification of Two RNA Modification Patterns and Tumor Microenvironment Infiltration Characterization of Lung Adenocarcinoma. | Front Genet | 2022 | 35154267 | PubTator, text mining | PubMed |
| Efficient in vitro and in vivo RNA editing via recruitment of endogenous ADARs using circular guide RNAs. | Nat Biotechnol | 2022 | 35145312 | PubTator, text mining | PubMed |
| Tracing the SARS-CoV-2 infection on the ocular surface: Overview and preliminary corneoscleral transcriptome sequencing. | Exp Eye Res | 2022 | 35134391 | PubTator, text mining | PubMed |
| ADAR1-mediated RNA editing links ganglioside catabolism to glioblastoma stem cell maintenance. | J Clin Invest | 2022 | 35133980 | PubTator, text mining | PubMed |
| Alu RNA Structural Features Modulate Immune Cell Activation and A-to-I Editing of Alu RNAs Is Diminished in Human Inflammatory Bowel Disease. | Front Immunol | 2022 | 35126398 | PubTator, text mining | PubMed |
| ADAR1- and ADAR2-mediated regulation of maturation and targeting of miR-376b to modulate GABA neurotransmitter catabolism. | J Biol Chem | 2022 | 35124003 | PubTator, text mining | PubMed |
| Angiogenic and molecular diversity determine hepatic melanoma metastasis and response to anti-angiogenic treatment. | J Transl Med | 2022 | 35109875 | PubTator, text mining | PubMed |
| Pan-Cancer Analysis Revealed SRSF9 as a New Biomarker for Prognosis and Immunotherapy. | J Oncol | 2022 | 35069733 | PubTator, text mining | PubMed |
| Impact of ADAR-induced editing of minor viral RNA populations on replication and transmission of SARS-CoV-2. | Proc Natl Acad Sci U S A | 2022 | 35064076 | PubTator, text mining | PubMed |
| Spatio-temporal dynamics of intra-host variability in SARS-CoV-2 genomes. | Nucleic Acids Res | 2022 | 35048970 | PubTator, text mining | PubMed |
| Comprehensive interrogation of the ADAR2 deaminase domain for engineering enhanced RNA editing activity and specificity. | Elife | 2022 | 35044296 | PubTator, text mining | PubMed |
| Genome-wide perturbations of Alu expression and Alu-associated post-transcriptional regulations distinguish oligodendroglioma from other gliomas. | Commun Biol | 2022 | 35042936 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/104/papers?page=25